Abstract
Purpose – to evaluate interactions between the value of circulating galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission. Materials and methods. One hundred fifty seven out subjects with chronic lymphocytic leukemia in full or partial remission were enrolled in the study. Observation period was up to 12 months. Blood samples for biomarkers measurements were collected at the visit of inclusion into the study. ELISA method for measurements of circulating level of galectin-3 was used. Cardiovascular events were evaluated for 3 year observation period. Results. Two hundred seventy cumulative clinical events occurred in 68 patients (43.3 %) within the follow-up, with their distribution being as follows: 12 deaths for cardiovascular reasons, 17 life-threatening arrhythmias, 36 cardiac ischemic events, 9 strokes, 38 decompensated chronic heart failures and 58 hospital admissions for cardiovascular reasons. Mean levels of galectin-3 in free-events subject cohort and subjects cohort with cardiovascular events were 5.22 ± 3.06 ng/ml and 12.64 ± 5.24 ng/ml (Р < 0.0001). In patients after antitumor treatment with anthracyclines mean levels of galectin-3 were higher in comparing with patients after antitumor treatment without anthracyclines (Р = 0.0014). There were no differences in the value of galectin-3 in depend on gender, age, cumulative dose of anthracyclines, arterial hypertension, hyperlipidemia, diabetes mellitus, body mass index, smoking. Conclusions. Among patients with chronic lymphocytic leukemia in remission increased circulating galectin-3 associates with presence of anthracyclines in antitumor treatment and increased cumulative cardiovascular events within 3 year observation period.
Highlights
One hundred fifty seven out subjects with chronic lymphocytic leukemia in full or partial remission were enrolled in the study
Cardiovascular events were evaluated for 3 year observation period
In patients after antitumor treatment with anthracyclines mean levels of galectin-3 were higher comparing with patients after antitumor treatment without anthracyclines (P = 0.0014)
Summary
Взаємозв’язки між галектином-3 та кардіоваскулярним ризиком у хворих із ремісією хронічної лімфоцитарної лейкемії: результати 3-річного проспективного дослідження. Мета роботи – виявлення взаємозв’язків між рівнем циркулюючого галектину-3 та кардіоваскулярним ризиком у пацієнтів із хронічною лімфоцитарною лейкемією в ремісії. Серед пацієнтів із документованою хронічною лімфоцитарною лейкемією в ремісії підвищення циркулюючого галектину-3 пов’язане з включенням антрациклінів у схеми протипухлинного лікування та асоціюється з виникненням кардіоваскулярних подій протягом 3 років спостереження. Взаимосвязи между галектином-3 и кардиоваскулярным риском у пациентов с ремиссией хронической лимфоцитарной лейкемии: результаты 3-летнего проспективного исследования. Цель работы – выявить взаимосвязи между уровнем циркулирующего галектина-3 и кардиоваскулярным риском у пациентов с хронической лимфоцитарной лейкемией в ремиссии. У пациентов с документированной хронической лимфоцитарной лейкемией в ремиссии повышение циркулирующего галектина-3 связано с включением антрациклинов в схемы противоопухолевой терапии и ассоциируется с возникновением кардиоваскулярных событий на протяжении 3 лет наблюдения. Purpose – to evaluate interactions between the value of circulating galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Current issues in pharmacy and medicine: science and practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
